ARCHIVES

NIH On R29 Phase-Out; Grant Review Appeals Process Changed

This article is from The Cancer Letter archive.

Vol. 24 No. 03 | January 23, 1998

Download PDF Visit The Full Archive

Related Articles

Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease

November 30, 2012

Montefore Oncology Dept. Writes In Support of Peter Wiernik

November 12, 1993

NIH Reauthorization Threatened By Fetal Research Issue

October 5, 1990

“Bring Contracts Under Control, Save $100,00 A Year,” Samuels Tells NCI

November 2, 1979

Rall Says NTP Must Have New Positions To Spend Extra $23 Million On Testing More Chemicals

September 7, 1979

“Optimal Criteria,” For Hospitals Treating Cancer Patients Developed; NCI Won’t Try Forcing Changes

November 1, 1974